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Sir,
We read with great interest a recent article by Gibault et al
(2005) regarding the role of various molecular markers in
squamous cell carcinoma of oesophagus (SCCO). We agree with
their conclusions that ErbB1 receptors are involved in oesophageal
carcinogenesis and prognosis, thus they may be potential targets
for immunotherapy of SCCO. However, we have a different view on
one of the issues addressed by the group regarding the role of
HER2 (ErbB2) in SCCO. In their article, they suggested that their
results are consistent with other studies but note a lack of
comparative data simply because, to their knowledge, studies
concerning ErbB2 expressions are very scarce since a study
reported by Shiga et al (1993). They therefore concluded that HER
2 (ErbB2) receptors nevertheless appear to be of poor interest as
potential therapeutic targets in SCCO.
Traditionally ErbB1 has been considered to be associated with
SCCO and majority of the studies have shown it to be over-
expressed and associated with poor prognosis in SCCO. However,
there is growing body of evidence showing ErbB2 is also
abnormally expressed in SCCO and associated with poor
prognosis. We reviewed studies reported since 1993 that have
analysed ErbB2 expression in SCCO in association with outcome of
the disease. Six studies have analysed ErbB2 overexpression in
SCCO using immunohistochemistry and ErbB2 has been found to
be overexpressed in 9% of cases in one study (Sunpaweravong
et al, 2005) and 26–64% of cases in the other five studies
(Hardwick et al, 1997; Friess et al, 1999; Wang et al, 1999;
Akamatsu et al, 2003; Mimura et al, 2005b). This rate of over
expression is greater than the one reported by Gibault et al (2.8%),
suggesting that ErbB2 is overexpressed to a greater extent in SCCO.
Of the six studies described above, two reported a statistically
significant association of ErbB2 overexpression with poor prog-
nosis (Mimura et al, 2005b; Sunpaweravong et al, 2005). ErbB2
overexpression has also been shown to be a marker of
chemoradioresistance (Akamatsu et al, 2003). Two studies, since
1993 have detected ErbB2 mRNA expression using PCR and
reported overexpression in 25 and 28% of cases (Tanaka et al,
1997; Miyazono et al, 2004). In these two studies ErbB2
overexpression has been associated with extramucosal tumour
invasion and poor response to chemoradiation.
Although methodologies used in these studies to detect ErbB2
expression are different but all of them clearly suggest that ErbB2
receptors are overexpressed in SCCO to a greater extent as
reported by Gibault et al. ErbB2 overexpression has also been
associated with invasive disease, poor response to treatment and
outcome. Early preclinical studies using Herceptin (anti HER 2
monoclonal antibody) in SCCO cell lines have shown that it does
have inhibitory effect on growth of cells, either alone or in
combination with conventional treatments (Mimura et al, 2005a;
Sato et al, 2005). On the basis of current evidence, which suggests
abnormalities of ErbB2 expression, its association with poor
prognosis and evidence that targeting it could be of therapeutic
benefit in SCCO, we cannot exclude the possibility of significant
role of HER 2 receptors in oesophageal squamous cell carcinogen-
esis, disease progression and its potential value as therapeutic
target, along with ErbB1.
ErbB2-targeted therapies are still in an early stages of
development in reference to SCCO and at this stage we look
forward to results evaluating its effects in other cancers, where
these therapies are in a relatively advanced stages of development.
We hope that further research in this field will help determine the
value of ErbB 1 and ErbB2 targeted therapies in SCCO.
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Sir,
At first, we would like to thank you for giving us the opportunity
to reply to this letter. It may be worth reminding that our study
was aimed at gaining insight, from only immunohistochemical
data, into the potential impact of several targets such as EGFR, Her
2, p53, VEGF and ckit in a large and homogenous series of patients
(107) with oesophageal squamous cell carcinoma. Our experiments
showed a potential impact of EGFR status, and HER2 was found to
be overexpressed by only 2.8% of the tumours (Gibault et al, 2005).
Before replying to the letter by Khan, it sounds us worth (i)
recalling that there is a consensus among the scientific community
about the difficulty of comparing data relative to the assessment of
angiogenesis by immunohistochemistry (Vermeulen et al, 2002)
and (ii) indicating that our bibliography section did not refer to
the two very interesting and recent papers by Mimura et al
(2005a,b) only because our manuscript had been submitted and
accepted before the publication of both articles.
The remarks by Khan and co-workers are focused on the low
rate reported by our team and on the potential role of HER2 in
squamous cell carcinoma of the oesophagus. We totally agree
with them about the fact that several analyses of HER2 carried out
by immunohistochemistry or other methods (Shiga et al, 1993;
Hardwick et al, 1997; Tanaka et al, 1997; Friess et al, 1999; Wang
et al, 1999; Akatmatsu et al, 2003; Miyazono et al, 2004; Mimura
et al, 2005a,b; Sato et al, 2005; Sunpaweravong et al, 2005) have all
found rates of overexpression greater than 2.8%. To our opinion,
the differences observed between these different studies have
several origins: the first of them, as clearly said by Khan and co-
workers is the high heterogeneity in the methodologies used in
the collection of studies cited by these authors. For example, Friess
studied adenocarcinoma and squamous cell carcinoma and used
an antibody and a semiquantitative procedure both different from
ours (Friess et al, 1999). Among the available methods, the Dako
Herceptest for immunohistochemical assay is considered as the
most reliable one for the detection of a positive HER-2 status; this
consideration drove us to use it and evaluate the staining as
described by Penault-Llorca et al (2002). Concerning Mimura and
co-workers, in addition to immunochemistry they performed a
Her2 gene amplification with the aim to optimise their search for
HER2 expression. However, by a careful reading of their paper
in Clinical Cancer Research (Mimura et al, 2005a) one learns
that, after the study of squamous cell lines, they analysed Her-2
expression in freshly isolated tumours (primary tumour and
malignant pleural infusion from two patients; both samples were
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